Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy shows promise for Drug-Resistant lung cancer

NCT ID NCT04606771

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This phase 2 trial tests whether adding savolitinib to osimertinib can shrink tumors or slow cancer growth in people with a specific type of advanced lung cancer (EGFR-mutated, MET-amplified) that has worsened despite osimertinib treatment. About 30 adults will receive either the drug combination or savolitinib with a placebo. The main goal is to see how many patients have their tumors shrink significantly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
savolitinib and osimertinib (drug combination)
What this could lead to
If it works, this could offer a new treatment option for people with a specific type of lung cancer that has stopped responding to standard therapy.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply broadly. The combination may not improve outcomes or could cause additional side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma Neoplasm Metastasis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

  • Research Site

    Duarte, California, 91010, United States

  • Research Site

    Sacramento, California, 95817, United States

  • Research Site

    Ciudad de Buenos Aires, C1120AAT, Argentina

  • Research Site

    Delhi, 110085, India

  • Research Site

    Mumbai, 400053, India

  • Research Site

    Taichung, 402, Taiwan

  • Research Site

    Taipei, 100, Taiwan

  • Research Site

    Taipei, 11217, Taiwan

  • Research Site

    Taipei, 235, Taiwan

  • Research Site

    Taoyuan City, 333, Taiwan

  • Research Site

    Bangkok, 10210, Thailand

  • Research Site

    Bangkok, 10300, Thailand

  • Research Site

    Bangkok, 10330, Thailand

  • Research Site

    Bangkok, 10400, Thailand

  • Research Site

    Bangkok, 10700, Thailand

  • Research Site

    Hat Yai, 90110, Thailand

  • Research Site

    Khon Kaen, 40002, Thailand

  • Research Site

    Muang, 50200, Thailand

  • Research Site

    Hanoi, 100000, Vietnam

  • Research Site

    Hà Nội, 100000, Vietnam

  • Research Site

    Ho Chi Minh City, 700000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.